SOMERSET, N.J., Aug. 21, 2013 – The Post-Finasteride Syndrome Foundation today announced the funding of a second major clinical study on post-finasteride syndrome (PFS), this one at Baylor College of Medicine (BCM) in Houston, Texas. Titled “Genetic and Epigenetic Studies on Post-Finasteride Syndrome Patients,” the research is being led by Mohit Khera (right), MD, MBA, […]
Tag Archives: Post-Finasteride Syndrome
Клиническое исследование постфинастеридного синдрома запущено в Бригаме и женской больнице
SOMERSET, N.J., July 1, 2013 – The Post-Finasteride Syndrome Foundation today announced the funding of a major clinical study on post-finasteride syndrome (PFS) at Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School. Titled “A Preliminary, Hypothesis-Generating Investigation of the Post-Finasteride Syndrome: Description of the Phenotype, and Elucidation of the Hormonal, Genetic […]
2018 Ежегодное обращение Фонда ПФС
Aug. 4, 2018 Dear Friends: November 23 is a day I wish I could strike forever from the calendar. For it’s the anniversary of my son Randy’s death. And this coming November 23 will be particularly difficult, marking a decade since his passing. On that day in 2008, despite my degrees from Johns Hopkins and […]
2018 PFS Foundation Annual Address
Aug. 4, 2018 Dear Friends: November 23 is a day I wish I could strike forever from the calendar. For it’s the anniversary of my son Randy’s death. And this coming November 23 will be particularly difficult, marking a decade since his passing. On that day in 2008, despite my degrees from Johns Hopkins and […]
Тезисы с февраля 2013 г. Обсуждение результатов исследования круглого стола PFS в Италии
SOMERSET, N.J., March 25, 2013 – The roundtable discussion at the 7th international steroids and nervous system meeting in Orbassano (TO), Italy, February 16th – 20th 2013, included scientific presentations and discussions amongst multiple medical researchers regarding the Post-Finasteride Syndrome. This event was a great opportunity for the PFS Foundation to increase awareness of PFS […]
Фонд пост-финастерид-синдром получил от IRS некоммерческий статус как общественная благотворительная организация
SOMERSET, N.J., March 18, 2013 – The Post-Finasteride Syndrome Foundation today announced that it has been granted 501(c)(3) status by the Internal Revenue Service. “Nonprofit status will allow us to put more dollars to work pursuing our core goal, which is funding research on the characterization, underlying biologic mechanisms and treatments of PFS,” added Dr. […]
Французское предупреждение о депрессии и суицидальных идеях, вызванных пропецией, вызывает волну внимания у СМИ
Dec. 19, 2017 Dear Friends: France is taking PFS very seriously. On Oct. 26, the French National Agency for Drug Safety (ANSM) issued a warning that “Changes in mood, particularly depression, and suicidal ideation, have been reported by patients taking Propecia.” The agency—France’s equivalent of the US Food and Drug Administration—noted that “finasteride treatment should […]
Годовой адрес Фонда PFS 2017
Aug. 4, 2017 Dear Friends: Recent events in Europe and Asia have given me hope that, before this decade is out, we’ll see the day when no man on earth is prescribed finasteride without ample warning of its many potential dangers. On May 24, the UK’s equivalent of the US Food and Drug Administration, the […]
Нормативно-правовое обновление: Корея предписывает изменение метки Пропеции на основании сообщений о депрессии и суицидальных идеях
May 26, 2017 Dear Friends: The UK’s equivalent of the US Food and Drug Administration, the Medicines and Healthcare Products Regulatory Agency (MHRA), has issued a drug safety update on finasteride. The May 24 document, titled Finasteride: rare reports of depression and suicidal thoughts, states: Some men have reported episodes of depressive illness in association with […]
132/5000 Исследование Эпидемиологии Школы Медицины им. Файнберга предполагает, что десятки тысяч случаев PFS у молодых мужчин принимают Финастерид для выпадения волос
SOMERSET, N.J., March 9, 2017 – More than one percent of young men who took finasteride for 206 days or longer developed persistent erectile dysfunction (PED) that lasted an average of 4.2 years after drug discontinuation, according to a new study published today in PeerJ. In all, researchers examined the electronic medical records (EMR) of […]